Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE).10,33 With regard to the secondary outcome of HF hospitalisation, the results were neutral, with LEADER showing a non-significant relative risk reduction (RRR) of 13% with liraglutide compared with placebo and SUSTAIN-6 showing no significant difference between the semaglutide and placebo treatment groups.10,33 Similarly, the REWIND trial, in patients with T2D and established CVD or cardiovascular risk factors, reported that dulaglutide significantly reduced the incidence of MACE (primary outcome)
[] In summary, glutamine has anti-inflammatory and cytoprotective properties
Use A pure NAC supplement that offers dual-action glu
[6] It's advisable to check specific airport and airline policies in advance
Can IV therapy prevent a hangover if done before drinking
Injectable semaglutide in the SUSTAIN trials showed comparable or slightly greater average weight loss at equivalent clinical doses, ranging from 10% to 15% across studies